A psychological Therapy for Hallucination

Not yet recruiting

• Conditions: Paranoid schizophrenia, (2) ICD-10 Condition: F203||Undifferentiated schizophrenia,

• Registration Number: CTRI/2022/01/039258
• Lead Sponsor: Devvarta Kumar

Brief Summary

The study is intended to develop a metacognitive intervention to assist individuals diagnosed with schizophrenia to have better insight into the hallucinatory experiences. The primary focus of therapy will be promoting metacognitive insight into the phenomenology of hallucinations and their cognitive and biological underpinnings. It will be followed by helping patients to relate the learning with their hallucinatory experiences. The whole module will be of 9 sessions of 45-60 minutes

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-06-01
• Study Start: 2022-10-01

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.Diagnosis of paranoid or undifferentiated schizophrenia 2.Age between 18-50 years 3.Education, at least, at primary level 4.Conversant in Hindi and/or English.

Exclusion Criteria

•Presence of Formal Thought Disorder •ECT in past 1 month •Alcohol or substance dependence.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in the severity of and insight into the hallucinatory experiences of patients with schizophrenia experiencing hallucination	Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up)

Secondary Outcome Measures

Name	Time	Method
Cognitive functions	The assessment will be done at baseline only
Global assessment of functioning	Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up)
Severity of positive and negative symptoms	Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up)
Perceived sense of recovery	Base-line, 5 weeks after baseline assessment (post-intervention), 9 weeks after baseline assessment (Follow-up)

Trial Locations

Locations (1)

National Institute of Mental Health and Neurosciences; 🇮🇳 Bangalore, KARNATAKA, India

National Institute of Mental Health and Neurosciences

🇮🇳Bangalore, KARNATAKA, India

Devvarta Kumar

Principal investigator

08026995188

devvarta.k@nimhans.ac.in